LBGCX
Price
$36.27
Change
-$0.00 (-0.00%)
Updated
Jun 22 closing price
Net Assets
281.5M
VMGMX
Price
$132.08
Change
+$0.31 (+0.24%)
Updated
Jun 22 closing price
Net Assets
33.76B
Interact to see
Advertisement

LBGCX vs VMGMX

LBGCX vs VMGMX Comparison Chart in %
View a ticker or compare two or three
VS
LBGCX vs. VMGMX commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LBGCX is a Hold and VMGMX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VMGMX has more cash in the bank: 33.8B vs. LBGCX (281M). VMGMX pays higher dividends than LBGCX: VMGMX (0.62) vs LBGCX (0.00). LBGCX was incepted earlier than VMGMX: LBGCX (16 years) vs VMGMX (15 years). LBGCX (1.99) is less costly to investors than VMGMX (0.07). LBGCX is a more actively managed with annual turnover of: 32.00 vs. VMGMX (17.00). LBGCX has a lower initial minimum investment than VMGMX: LBGCX (1000) vs VMGMX (3000). VMGMX annual gain was more profitable for investors over the last year : 11.76 vs. LBGCX (-0.77). VMGMX return over 5 years is better than : 31.10 vs. LBGCX (0.55).
LBGCXVMGMXLBGCX / VMGMX
Total Expense Ratio1.950.072,786%
Annual Report Gross Expense Ratio1.990.072,843%
Fund Existence16 years15 years-
Gain YTD4.9489.95250%
Front LoadN/AN/A-
Min. Initial Investment1000300033%
Min. Initial Investment IRAN/AN/A-
Net Assets281M33.8B1%
Annual Yield % from dividends0.000.62-
Returns for 1 year-0.7711.76-7%
Returns for 3 years30.5155.5355%
Returns for 5 years0.5531.102%
Returns for 10 years73.79213.1335%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TEMUX22.59N/A
N/A
Morgan Stanley Pathway Em Mkts Eq
MRICX26.84N/A
N/A
MFS Research International C
ICSSX16.85N/A
N/A
VY® Columbia Small Cp Val & InflectionS
ALVDX11.09N/A
N/A
American Century Focused Lg Cap Val R6
BRUMX18.35N/A
N/A
MFS Blended Research Value Equity R4